ArrayExpress Uploaderarrayexpress_sidhumanER posIII41HER2negPositiveT4b2.9Not-IBCER posIII53HER2negNegativeT4b4.1Not-IBCER posII54HER2negPositiveT4d9IBCER negIII32HER2negPositiveT4b6.7Not-IBCER posIII67HER2negPositiveT4b11Not-IBCER negIII54HER2posPositiveT4b2.7Not-IBCER negIII51HER2posNegativeT4b4.6Not-IBCER negIII62HER2negPositiveT4bNANot-IBCER posIII80HER2posPositiveT4b5Not-IBCER posIII49HER2negPositiveT4b6Not-IBCER posII61HER2posPositiveT4b15Not-IBCER negIII68HER2negPositiveT4b4.7Not-IBCER negIII46HER2negPositiveT4b3.1Not-IBCER negIII52HER2negPositiveT4bNANot-IBCER posIII46HER2posPositiveT4b7.7Not-IBCER posIII69HER2negPositiveT4b4.9Not-IBCER negIII49HER2negNegativeT4b17Not-IBCER posII52HER2negPositiveT4b3Not-IBCER negIII50HER2negPositiveT4b5Not-IBCER posII50HER2negPositiveT4b8.8Not-IBCER negIII46HER2posPositiveT4b3.3Not-IBCER posIII59HER2negPositiveT4b6Not-IBCER negII73HER2negPositiveT4b3Not-IBCER negIII62HER2negPositiveT4b8Not-IBCER posIII72HER2negPositiveT4bNANot-IBCER negIII60HER2posPositiveT4b12Not-IBCER negIII50HER2negPositiveT4bNANot-IBCER negIII56HER2posNegativeT4c4.5Not-IBCER negII52HER2negPositiveT4b6.9Not-IBCER posIII27HER2posPositiveT4b3.5Not-IBCER posII64HER2negPositiveT4b4.2Not-IBCER negIII61HER2negPositiveT4b4Not-IBCER posIII24HER2posPositiveT4b7Not-IBCER negIII39HER2negPositiveT4b4.5Not-IBCER posII58HER2negPositiveT4b6Not-IBCER posII53HER2negPositiveT4b8Not-IBCER posIII49HER2posPositiveT4c15Not-IBCER posII64HER2negPositiveT4b10Not-IBCER posII49HER2negNegativeT4b4Not-IBCER posIII71HER2posPositiveT4b5.5Not-IBCER posIII46HER2negPositiveT4b6Not-IBCER posIII67HER2negNegativeT4b5Not-IBCER negIII36HER2posPositiveT4b4.2Not-IBCER negIII39HER2posPositiveT4b9Not-IBCER posII48HER2negPositiveT4b4.9Not-IBCER negIII60HER2negPositiveT4b7.8Not-IBCER posII53HER2negPositiveT4b3.8Not-IBCER posIII38HER2negNegativeT4b7.5Not-IBCER posIII31HER2negPositiveT4b6Not-IBCER posIII38HER2negPositiveT4b7.2Not-IBCER negIII56HER2negPositiveT4b10Not-IBCER posII77HER2posPositiveT4b4Not-IBCER negIII51HER2negPositiveT4b10Not-IBCER negIII41HER2negPositiveT4b7Not-IBCER negIII58HER2negNegativeT4b6Not-IBCER posIII38HER2posPositiveT4b5.5Not-IBCER negIII49HER2posPositiveT4b12Not-IBCER posII45HER2negPositiveT4d2.3IBCER negIII32HER2negPositiveT4d4IBCER negIII30HER2posPositiveT4d7IBCER negIII62HER2negPositiveT4d6IBCER posII46HER2negPositiveT4d5IBCER posIII55HER2negPositiveT4d7.3IBCER negIII46HER2posPositiveT4d0IBCER negIII42HER2posPositiveT4d0.9IBCER negIII40HER2negPositiveT4d4IBCER negIII48HER2negPositiveT4d1.8IBCER negIII46HER2posPositiveT4d8IBCER negIII38HER2negPositiveT4d10IBCER negIII51HER2posPositiveT4d3.6IBCER negIII64HER2negPositiveT4d12.5IBCER posIII45HER2negPositiveT4b12Not-IBCER negIII55HER2posPositiveT4d1.6IBCER posIII78HER2posPositiveT4d2IBCER negIII47HER2posPositiveT4d1.6IBCER negIII45HER2negPositiveT4d4IBCER posIII32HER2negPositiveT4d3IBCER negIII58HER2posPositiveT4d3.6IBCER negIII29HER2negPositiveT4dNAIBCER negIII60HER2posPositiveT4d8IBCER negIII58HER2posPositiveT4d5.1IBCER negIII48HER2posPositiveT4d1.1IBC129303This is a stage-matched case control study. Cases with clinical diagnosis of Inflammatory Breast Cancer (IBC) were selected after...E-GEOD-22597/profile/8773/arrayexpressuploader882breastbreast cancercancerhormoneskinDec.12, 2014Falseexpression-data-from-fine-needle-aspiration-fna-biE-GEOD-22597_A-AFFY-33Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patientsJun.18, 2014This is a stage-matched case control study. Cases with clinical diagnosis of Inflammatory Breast Cancer (IBC) were selected after reviewing all medical records of the 440 FNA samples. IBC was defined as signs of erythema and edema (peau d’orange) involving at least one third of the skin and rapid clinical presentation. Presence of tumor emboli in the dermal lymphatics of the involved skin in the pathology report was not required for inclusion as IBC. Controls were selected to match for T stage, all T4a-c tumors in the data set were included as controls. IBC breast cancer are all T4d breast cancer. We examined if gene expression differences exist between IBC and stage-matched Non-IBC stratified according to hormone receptor and HER2 status. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22597http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-22597/samples/